Dr Julie L. Gerberding to retire from Merck as Chief Patient Officer
Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16
Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16
Serina has over 17 years of experience in the biopharmaceutical industry
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
Innovative TIMScore for dda-PASEF and dia-PASEF libraries, combined with TIMS DIA-NN identifies 9000 protein groups from 200 ng K562 lysate in just 35 min gradient
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
In this role, Jeffrey DeAlmeida takes responsibility for BASF’s global pharmaceutical solutions portfolio and the Nutrition & Health business in North and South America
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Citizens will be able to create their ABHA (Ayushman Bharat Health Account) numbers, to which their digital health records can be linked
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
Subscribe To Our Newsletter & Stay Updated